

Purdue Research Park  
3000 Kent Avenue, Suite C1-100  
West Lafayette, IN 47906-1075

Main: USA +1 765.464.8414  
Fax: USA +1 765.464.8408

[info@parsolexinc.com](mailto:info@parsolexinc.com)

## **Purdue GMP Center now operates as Parsolex**

October 29, 2019

West Lafayette, IN (October 29, 2019) – Purdue GMP Center, Inc. (“PGC”) is now operating as Parsolex GMP Center, Inc., doing business as Parsolex.

“We believe that a name change is appropriate at this time due to the launch of our capital investment program to evolve our company’s capabilities to serve the pharmaceutical industry,” said Alfonso Chang, CEO of Parsolex. “We are making significant investments in adding experts and professionals to our staff, analytical instrumentation, development technologies, and manufacturing equipment, as well as in renovating our West Lafayette, Indiana facility, so that we can better serve our clients with their evolving needs.”

The name “Parsolex” was identified and selected by the employees as the best method to describe the company, as it combines the concepts of partnership, solutions, and excellence.

“These three words describe what we strive to do perfectly,” said Chang. “We want to work with our clients, as partners, to find the most optimal and innovative solutions to their challenges, in an experience that exudes excellence.”

The company launched in 2004 and started operations in 2005 as The Chao Center for Industrial Pharmacy and Contract Manufacturing as an initiative of the Purdue Research Foundation to support Purdue University. Today, the company’s reach goes beyond Purdue University, as clients now include not only other leading academic institutions but also major hospital systems, start-up’s, virtual companies, and large multinational pharmaceutical companies from around the globe.

“While we are proud of the company’s history and its achievements thus far, we are even more excited for the company’s future and opportunities to accomplish much more for our clients,” said Dr. Michael Chao, Chairman of Parsolex. “We initiated our capital investment program with the corporate goal of making Parsolex the organization where clients feel confident their technical and commercial challenges can be solved.”

To learn more about Parsolex and its capabilities, please visit [www.parsolexinc.com](http://www.parsolexinc.com). Parsolex will also be exhibiting at the American Association of Pharmaceutical Scientists ("AAPS") PharmSci 360, November 3-6, 2019 in San Antonio, Texas, Booth 918.

Contact:

David A. Engers, PhD  
Parsolex  
Director, Client Services  
(765) 464-8414

Parsolex is derived from the words "Partner, Solutions, Excellence" – the foundation of everything we do. Since 2004, our experienced team has been committed to innovation in product and process design, development, CGMP manufacturing, and testing of solid oral dosage forms. We strive to achieve the success of all our clients to improve patient lives around the world. Parsolex operates a CGMP facility equipped with state-of-the-art manufacturing and analytical technologies located in West Lafayette, Indiana, USA, that is registered with the US Food & Drug Administration. Parsolex's technical capabilities include formulation and process development, including first-in-human strategies; clinical trial material ("CTM") manufacturing, scale-up, and technology transfer for a broad range of oral solid dosage forms, including but not limited to tablets, film-coated tablets, and hard gelatin capsules filled with powder, granule, and coated-beads; analytical method development and validation services; ICH stability storage; CGMP warehousing; and CGMP commercial manufacturing. Furthermore, Parsolex offers commercialization and strategic advisory services. For more information about Parsolex's capabilities, please contact +1 (765) 464-8414. Learn more at [www.parsolexinc.com](http://www.parsolexinc.com).